ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
Stopped Decision Board no further financial support after 3 years of follow-up as remaining patients in follow-up phase would not relevantly change the endpoints.
Conditions
- Prostate Cancer Metastatic
- Prostate Cancer
Interventions
- DRUG: ODM-201
- OTHER: Placebo
Sponsor
Swiss Cancer Institute